NGNE · Neurogene Inc.
$32.41
-0.82 (-2.45%)
At close · Jul 29
Market Cap
$524.94M
Shares
15.80M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$33.22
Open$34.13
Day$32.87–34.33
52W$15.93–43.66
Avg vol 30d278K
Short int2.9M · 18.5% float · 7.6d
Short vol56%
Last earningsAug 11, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+32%
above
Price vs 50-day avg
+4%
above
RSI (14)
45
neutral
MACD trend
Negative
52-week position
62%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+81%
trailing
YTD return
+61%
this year
Relative strength
+74%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $32 › 200d $25 — 50d above 200d
Institutional flow
Distributing
11 of 97 funds reported for Jun 30 · net -472 sh shares · +2 new
Insider flow
Distributing
Net -$300.0K over 90 days · 100% sells
Short interest
Falling
18.53% of float · ▼ -12.7% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 2-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+1%
Y/Y
Free cash flow
$-78.4M
Balance sheet
$103.8M
net cash
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+32%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
62%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $32 › 200d $25 — 50d above 200d
Institutional flow
Distributing
11 of 97 funds reported for Jun 30 · net -472 sh shares · +2 new
Insider flow
Distributing
Net -$300.0K over 90 days · 100% sells
Short interest
Falling
18.53% of float · ▼ -12.7% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $16
Now $33 · 62%
52-wk high $44
vs 200-day avg +32%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NGNE
this stock
Neurogene Inc.
|
$524.94M | +61.3% | -100.0% | — | 18.5% |
|
ONC
BeOne Medicines Ltd.
|
$473.24B | +7.3% | +22179.2% | 963.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NGNE | -11.0% | +3.7% | +81.2% | +5.6% | +61.3% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -10.0% | +3.7% | +73.8% | +6.4% | +52.6% |